Home > Insider Trading > Filing (0001213900-20-003326)

Filing Details

Accession Number:: 0001213900-20-003326
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-11 20:00:51
Reporting Period:: 2020-02-07

Accepted Time:: 2020-02-11 20:00:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658247	Crinetics Pharmaceuticals Inc.	CRNX	()	1231

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1618788	Vivo Capital Fund Viii, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1618789	Vivo Capital Viii, Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1628048	Vivo Capital Surplus Fund Viii, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1726403	Vivo Opportunity Fund, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No
1728970	Vivo Opportunity, Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-02-07	1,134	$22.00	2,723,843	No	4	S	Indirect	See foonotes
Common Stock	Disposition	2020-02-07	157	$22.00	376,128	No	4	S	Indirect	See foonotes
Common Stock	Disposition	2020-02-07	4,614	$22.00	174,202	No	4	S	Indirect	See foonotes
Common Stock	Disposition	2020-02-10	1,451	$21.40	2,722,392	No	4	S	Indirect	See foonotes
Common Stock	Disposition	2020-02-10	200	$21.40	375,928	No	4	S	Indirect	See foonotes
Common Stock	Disposition	2020-02-10	5,904	$21.40	168,298	No	4	S	Indirect	See foonotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See foonotes
No	4	S	Indirect	See foonotes
No	4	S	Indirect	See foonotes
No	4	S	Indirect	See foonotes
No	4	S	Indirect	See foonotes
No	4	S	Indirect	See foonotes

Footnotes

These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").
Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4 to $21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4